Loading...
01/11 05:01
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a challenging financial situation with declining revenue, gross margin, and increased net loss. Despite a positive backlog and future purchase commitments, the weak financial performance and negative adjusted EBITDA are concerning. The Q&A highlights unresolved issues like tariffs and production delays, although management remains optimistic about future growth. However, the lack of clear guidance on key developments and ongoing expenses further clouds the outlook, suggesting a negative stock price movement in the short term.
Revenue $4,200,000 (down from $5,200,000 in Q3 FY24), with production revenue at $3,200,000 (up from $3,000,000) and engineering revenue at $924,000 (down from $2,300,000). The decrease in overall revenue was due to low yields and production pauses, which led to unplanned increases in non-billable engineering activities.
Gross Margin 10% (down from 35% in Q3 FY24). The decline was attributed to low yields, a one-month shutdown of the production line, and under absorption of engineering resources.
Net Loss $2,100,000 (compared to a net loss of $317,000 in Q3 FY24). The increase in net loss was primarily due to lower revenue and associated lower gross profit.
Adjusted EBITDA Negative $1,300,000 (compared to positive $52,000 in Q3 FY24). The negative adjusted EBITDA was a result of lower production and engineering revenue.
R&D Spending $211,000 (up from $193,000 in Q3 FY24). The increase was primarily due to investments in the Unity platform.
SG&A Expenses $2,200,000 (up from $1,900,000 in Q3 FY24). The increase was primarily due to higher personnel costs, including stock-based compensation and recruiting expenses.
Cash Position Excess of $2,500,000 at the end of March 2025. During the quarter, approximately $5,000,000 was raised, which was used to pay down the revolving line of credit and deploy working capital.
Aerospace Program Revenue Increased from approximately $300,000 in Q1 to $600,000 in Q2 to just under $900,000 in Q3. This growth is expected to continue into Q4.
Backlog Greater than $6,000,000, providing predictability and visibility to the growing production schedule.
Minimum Annual Purchase Commitment Nearly $4,000,000 for 2025 and 2026 from a key customer, indicating strong future revenue potential.
Unity Platform Launch: The Unity platform was launched in late January, designed to utilize standard baseline designs with modular subsystems for quick updates and customization.
Single Use Cystoscope Production: Production of the single use cystoscope was paused due to low yields but has since resumed with improved throughput, expected to contribute significantly to Q4 revenue.
New Product Development: Started production of a microendoscope for ophthalmic procedures and a complex subassembly for retinal imaging, each generating $100,000 to $200,000 per quarter.
Aerospace Program Growth: Production revenue from the aerospace program increased from $300,000 in Q1 to $900,000 in Q3, with expectations to double output in Q4.
Market Demand for Single Use Endoscopes: The single use endoscope market is growing at annual rates estimated to be as high as 20%, driven by lower costs and superior performance.
Production Challenges: Faced production challenges leading to lower revenue and margins, with a shortfall of approximately $600,000 in Q3 due to low yields and engineering resource allocation.
Staffing Improvements: Significant progress in staffing assembly technicians has been made, with current throughput on the endoscope line now double pre-shutdown levels.
Board Changes: Two new board members, Buell Duncan and JJ Pellegrino, bring extensive experience in corporate management and scaling production in the medical device sector.
Long-term Customer Commitment: A new agreement with a military customer includes minimum annual purchase commitments of nearly $4,000,000 for 2025 and 2026, indicating strong future revenue potential.
Production Challenges: Encountered significant production challenges leading to lower revenue and margins, including low yields, delivery delays, and reduced efficiency.
Engineering Resource Allocation: Engineering resources were diverted to resolve production issues, impacting billable engineering projects and resulting in a shortfall of approximately $600,000 in Q3.
Staffing Issues: Challenges in recruiting, retaining, and training assembly technicians, particularly for second shifts, affected production ramp-up.
Regulatory and Compliance Risks: Potential risks associated with tariffs impacting sourcing of components from overseas, particularly affecting the Ross Optical business.
Customer Relationships: While production delays disappointed customers, strong relationships mitigated risks of losing contracts or customers to competitors.
Market Competition: The company faces competitive pressures in the endoscope market, which is rapidly evolving with new technologies.
Economic Factors: Overall economic conditions and potential tariff impacts could affect cost structures and pricing strategies.
Production Backlog: The company has the largest production backlog in over twenty years, indicating strong demand for their products.
Unity Platform: The Unity platform was launched to streamline the development of endoscopic systems, expected to reduce time to market by 6-12 months.
Aerospace Program: Production levels from the aerospace program are expected to set new records in Q4, with a commitment of nearly $4,000,000 in annual purchase agreements.
Single Use Cystoscope: The company is expanding output of the single use cystoscope and plans to add a second production line in the first half of fiscal 2026.
Revenue Expectations: The company expects to achieve $6,000,000 in sales in the next quarter, with strong demand for production.
Gross Margin Recovery: Gross margin is expected to recover as manufacturing scales and revenues increase, particularly in Q4.
Adjusted EBITDA: The company anticipates reaching positive adjusted EBITDA in Q4.
R&D Spending: R&D spending is expected to remain steady, with no significant increases anticipated in the near term.
Annual Purchase Commitment: The customer has agreed to minimum annual purchase commitments of nearly $4,000,000 for 2025 and 2026.
Backlog: The company has a backlog greater than $6,000,000 today.
Production Revenue: Production revenue was $3,200,000 compared to $3,000,000 in the year ago quarter.
Expected Q4 Revenue: The company expects to finish the fiscal year strongly with $6,000,000 in sales in the next quarter.
Net Loss: The net loss was $2,100,000 for the quarter compared to $317,000 net loss for the same quarter last year.
Adjusted EBITDA: Adjusted EBITDA was negative $1,300,000 in the third quarter of twenty twenty five.
The earnings call indicates strong revenue growth, especially in key manufacturing programs, and an optimistic outlook for fiscal 2026 with improved gross margins and positive adjusted EBITDA. The Q&A section did not reveal significant negative trends, and the company's strategic expansion into defense aerospace alongside medical devices suggests diversification and potential profitability. Despite some concerns over gross margins and delayed orders, the overall sentiment is positive, supported by strong revenue expectations and strategic operational investments.
The earnings call reveals record-high quarterly revenue and a significant increase in production revenue, despite a decline in gross margin. The Q&A section confirms conservative but optimistic guidance, with expectations of improved gross margins and a well-prepared pipeline. Management's clear responses and strategic focus on production and engineering projects suggest a positive outlook. The stock price is likely to react positively, with potential gains of 2% to 8% over the next two weeks.
The earnings call reflects significant challenges: a steep decline in gross margins, increased net losses, and staffing issues. The Q&A highlighted uncertainties about engineering revenue and production delays, although management expressed optimism about resolving these issues. Despite a $5 million raise to improve financial health, there's no immediate shareholder return plan. The military program's continuity is positive, but overall, the financial performance and lack of clear guidance on key issues suggest a negative sentiment. The market is likely to react negatively, with a potential stock price decrease between -2% and -8%.
The earnings call reveals a challenging financial situation with declining revenue, gross margin, and increased net loss. Despite a positive backlog and future purchase commitments, the weak financial performance and negative adjusted EBITDA are concerning. The Q&A highlights unresolved issues like tariffs and production delays, although management remains optimistic about future growth. However, the lack of clear guidance on key developments and ongoing expenses further clouds the outlook, suggesting a negative stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
